Merck to start the proof of concept for the Study of posaconazole chronic Chagas disease, recognized by WHO as one of the WHITEHOUSE STATION … NJ —- Merck announced plans to initiate a Phase II proof of concept research trials to assess oral antifungal agent posaconazole the treatment of chronic Chagas disease.
HOW TO CURE YEAST INFECTION FAST !!